Azetukalner

DB21551InvestigationalSmall molecule

Azetukalner is a small molecule drug. The usage of the INN stem '-kalner' in the name indicates that Azetukalner is a opener of calcium-activated (maxi-K) K+-channel. Azetukalner is under investigation... Azetukalner is under investigation in clinical trial NCT05718817 (An Open-label Study of XEN1101 in Epilepsy).

Mechanism: Pharmacologically active on Potassium voltage-gated channel subfamily KQT member 2 and Potassium voltage-gated channel subfamily KQT member 3
Curator reviewed
Formula / weight: C₂₃H₂₉FN₂O · 368.496 g/mol (avg)
Code names: XEN-1101

Resolves to

Compound

UNII91WL7OD122CAS1009344-33-5ChEMBLCHEMBL5095264ChEBI758840PubChem24743936

Structure

InChIKeyFJNPZKZPWVVSON-UHFFFAOYSA-NSMILESCC1=CC(=CC(C)=C1NC(=O)CC(C)(C)C)N1CCC2=C(C1)C=CC(F)=C2

Targets

O43526KCNQ2O43525KCNQ3

What you can answer from here — as of September 23, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

13Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Azetukalner, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account